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Molecular Marker in Adenoid
Cystic Carcinoma of the Salivary
Glands: Implications for Clinical
Significance1,2JanyapornPhuchareon*,†, Jonathan B. Overdevest*,
Frank McCormick†, David W. Eisele*,†,
Annemieke van Zante‡ and Osamu Tetsu*,†
*Head and Neck Cancer Research Laboratory, Department
of Otolaryngology-Head and Neck Surgery, School of
Medicine, University of California, San Francisco, CA, USA;
†UCSF Helen Diller Family Comprehensive Cancer Center,
School of Medicine, University of California, San Francisco,
CA, USA; ‡Department of Pathology, School of Medicine,
University of California, San Francisco, CA, USAAbstract
Adenoid cystic carcinoma (ACC) is an aggressive malignant neoplasm of the salivary glands. Its diagnosis is
difficult due to overlapping features with other salivary tumors. Gene expression analysis may complement
traditional diagnostic methods. We searched gene expression patterns in the Gene Expression Omnibus (GEO)
database and in our tumor and normal samples. The biologic and prognostic potential of the identified genes was
analyzed. The GEO data set of primary xenografted ACCs revealed that expression of five genes, engrailed
homeobox 1 (EN1), fatty acid binding protein 7 (FABP7), hemoglobin epsilon 1, MYB, and versican (VCAN), was
dramatically increased. mRNA expression of EN1, FABP7, MYB, and VCAN distinguished our sporadic ACCs from
normal tissues and benign tumors. FABP7 expression appeared to be regulated differently from EN1 andMYB and
was crossly correlated with poor prognosis in our ACC cohort. Immunohistochemistry showed that FABP7 protein
was predominantly expressed in the nucleus of myoepithelial cells of both tubular and cribriform subtypes. In
contrast, in the solid subtype, which is often associated with a lower survival rate, FABP7 protein was uniformly
expressed in cancerous cells. One case with cribriform architecture and the highest level of FABP7mRNA showed
strong FABP7 staining in both duct-type epithelial and myoepithelial cells, suggesting that diffuse expression of
FABP7 protein might be related to aggressive tumor behavior and poor prognosis. We propose FABP7 as a novel
biomarker in ACC. The molecule may be useful in diagnosis and for identifying more effective therapies targeting
this protein or upstream molecules that regulate it.
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Adenoid cystic carcinoma (ACC) is a high-grade malignant neoplasm
of the salivary glands with unique histology and variable clinical
behavior [1–5]. ACC has a propensity to metastasize extensively and
the long-term prognosis is not favorable. Distant metastases can
develop despite local and regional tumor control and can be delayed,
sometimes occurring 10 to 20 years after diagnosis. Unfortunately,
therapeutic options for ACC are limited and usually consist of surgery
and postoperative radiation therapy. These interventions, however,
have failed to affect long-term outcomes in ACC.
The diagnosis of ACC is another challenge. Existing imaging
methods, including ultrasonography, computed tomography, mag-
netic resonance imaging (MRI), and radionuclide scanning, do not
Translational Oncology Vol. 7, No. 6, 2014 FABP7 is a biomarker in adenoid cystic carcinoma Phuchareon et al. 781provide a definitive diagnosis [6,7]. Evaluation of fine needle
aspiration biopsy material is not always reliable diagnostically, due
to the overlapping microscopic features between ACC and other
salivary gland neoplasms [8–10]. Accurate diagnosis, however, is
important to guide proper surgery and adjuvant treatment [1–5].
Gene expression analysis will likely be an important complement to
traditional diagnostic methods in the diagnosis of ACC [11,12]. As
an example, immunohistochemical staining for c-Kit is often used
in conjunction with histology to aid in diagnosis of ACC. c-Kit, a
proto-oncogene, is overexpressed in almost all ACCs but seldom
increased in other head and neck tumors [3–5].
Other potential diagnostic markers for ACC have been reported. For
example, t(6;9) chromosomal translocations involving genes encoding
transcription factors MYB and nuclear factor I/B have been found in
roughly half of ACCs [13,14]. In addition, a gene expression profile of
ACC found elevated expression of a variety of extracellular matrix gene
products, including versican (VCAN) [15]. More recently, engrailed
homeobox 1 (EN1)was reported as a biomarker for ACC [16]. However,
it is not clear whether these molecules were increased specifically in
ACC or to what extent they contribute to its malignant growth,
metastasis, and prognosis. The objective of this study was to identify a
diagnostic molecular marker for ACC, which would be a predictor of
the prognosis and a possible therapeutic target. With a biomarker,
advances in ACC management may be possible [2].
We searched the Gene Expression Omnibus (GEO) database for
potential diagnostic biomarkers of ACC. Expression microarrays of 11
primary xenografted ACCs revealed that levels of EN1, fatty acid binding
protein 7 (FABP7; also known as brain lipid binding protein), hemoglobin
epsilon 1 (HBE1),MYB, and VCAN were elevated compared to normal
salivary tissues and were the five most elevated genes [17]. Similar
findings were obtained from 27 tumor samples of sporadic ACCs in our
archives. We found that expression of EN1, FABP7, MYB, and VCAN
were considerably elevated. Expression of these genes distinguished
ACCs from normal salivary tissues and benign tumors, including basal
cell adenomas (BCAs) and pleomorphic adenomas (PAs).HBE1was not
detectable with our extracts. We also observed a correlation between
FABP7 expression and overall survival in ACC, suggesting that FABP7
might have prognostic value in patients with ACC.
This study proposes that FABP7 is a biomarker that can be used to
diagnose ACC, aid tumor screening, help delineate surgical margins,
predict prognosis, monitor patients in remission, and is a starting point for
more effective therapeutic options.Wediscuss a potential role of FABP7 in
ACCbased on its subcellular distribution and cell type–specific expression.
Materials and Methods
Tumor and Normal Samples
We obtained 27 ACCs, 4 BCAs, and 5 PAs, as well as 5 normal
salivary tissue samples from the University of California, San Francisco
(UCSF) Anatomic Pathology archives. Institutional review board (IRB)
approval was obtained and UCSF guidelines for handling human tissue
were followed. Representative normal salivary tissues were additionally
chosen from ACC patients whose tumor samples were included in this
study. Slides were reviewed to determine tissue suitability for gene
expression analysis.TaqMan Quantitative Polymerase Chain Reaction Assay
Gene expression was analyzed in triplicate with TaqMan quantitative
polymerase chain reaction (qPCR). Total RNA was isolated usingRNAeasy kits (Qiagen, Valencia, CA) from formalin-fixed, paraffin-
embedded tumor tissue sections composed of at least 70% tumor cells.
cDNA from 500 ng of total RNA was synthesized with an RT first-
strand kit (Life Technologies, Carlsbad, CA). cDNA (5 ng) was mixed
with transcriptase (RT) qPCR master mixes, and aliquots were placed
with gene-specific primer sets. The following TaqMan assays (all from
Life Technologies) were used: EN1 (Hs00154977_m1), FABP7
(Hs00361426_m1), HBE1 (Hs00362216_m1), VCAN
(Hs00171642_m1), and MYB (Hs00920554_m1). Expression levels
normalized to endogenous glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were determined by real-time PCR and analyzed at the
UCSF Comprehensive Cancer Center Genome Analysis Core Facility.
Fold changes in gene expression were calculated as the ratio of
expression in each sample to average expression in controls. Statistical
analyses and graphs were made using Microsoft Office Excel and
XLSTAT (Addinsoft, New York, NY). Statistical comparisons between
data sets were made with two-tailed Student’s t tests and log rank tests,
and P b .05 was considered significant.
Immunohistochemistry
Immunohistochemistry was performed on unstained sections using
antibody-based staining kits for FABP7 (AF3166; R&D Systems,
Minneapolis, MN) or goat isotype control (AB-108-C; R&D
Systems) at the UCSF Comprehensive Cancer Center Immunohis-
tochemistry and Molecular Pathology Core Facility. The detailed
procedure for staining has been described [3]. FABP7 staining was
visually estimated by a head and neck pathologist (A.v.Z.).
Results
Tumor Characteristics
A total of 41 samples of salivary tissues from the UCSF archives was
included in this study: 27 cases of ACC, 4 BCAs, 5 PAs, and 5 normal
salivary gland samples.We included BCAs and PAs in the study because
the microscopic features of these tumors often overlap with those of
ACC, and distinguishing them is important for appropriate manage-
ment of patients with salivary gland tumors. All tumors had arisen
sporadically. Sixteen ACC tumors occurred in women. The median age
at presentation was 58 years (range, 33-91 years). Tumors arose at the
following sites: maxillary sinus (nine tumors), submandibular gland (six
tumors), parotid gland (five tumors), sublingual gland (two tumors),
and one each in the nasal cavity, mandibularmucosa, nasopharynx, base
of tongue, and tongue. Tumors were classified bymorphologic subtype:
tubular (4 cases), cribriform (3), solid (1), combined cribriform and
tubular (10), combined solid and tubular (8), and combined cribriform
and solid (1). In the BCAs, all four tumors occurred inwomen and arose
in the parotid gland. Median age at presentation was 60 years (range,
40-73 years). In the PAs, three tumors occurred in women.Median age
at presentation was 46 years (range, 20-67 years), and four tumors arose
in the parotid gland with one in the submandibular gland. Two of five
normal salivary tissue specimens were from women. Median age at
presentation was 62 years (range, 33-91 years). Three samples
represented tissue excised from the submandibular gland; two were
from the parotid gland.Expression of EN1, FABP7,MYB, andVCANDistinguishes ACCs
from Normal Tissues and Benign Tumors in the Salivary Glands
In our search of the GEO database, we obtained gene expression
profiles of 11 primary xenografted ACCs and 3 normal salivary gland
782 FABP7 is a biomarker in adenoid cystic carcinoma Phuchareon et al. Translational Oncology Vol. 7, No. 6, 2014tissue samples (Accession No. GSE36820). One of the most important
applications of the GEO data set to ACC pathobiology is to identify
diagnostic markers [18]. To find differentially expressed genes in the
data set, we compared fold changes rather than the t-statistics because
we considered that larger absolute changes in gene expression would be
more practical for identifying diagnostic markers [19]. We found
increased expression of the following genes in primary xenografted ACC
tumors: EN1, FABP7, HBE1, MYB, and VCAN. Their log2 fold
changes were 6.04 (EN1), 6.01 (FABP7), 5.96 (HBE1), 5.41 (MYB),
and 5.24 (VCAN), meaning that these genes increased their expression
by 65.8-fold (EN1), 64.4-fold (FABP7), 62.2-fold (HBE1), 42.5-fold
(MYB), and 37.8-fold (VCAN).
We then investigated whether the expression of these genes would also
be elevated in sporadic ACCs from our archives. mRNA was isolated
from formalin-fixed, paraffin-embedded sections as described, and
qPCR was performed. Figure 1 shows that mRNA expression of EN1,
FABP7, MYB, or VCAN was elevated in ACC (P b .05; Figure 1, A–D).
Our probe did not detectHBE1 in these extracts. The relative expression
of EN1 (increased by 848-fold over the average of normal samples) and
MYB (increased by 659-fold over the average of normal samples)
distinguished ACC from normal tissues and benign tumors (Figure 1, A
and C). FABP7 mRNA in ACC was overexpressed relative to normal
salivary glands (P = 2.7 × 10−10; Figure 1B), as well as BCA and PA (P =
1.1 × 10−2 and 5.0 × 10−3, respectively). VCAN ’s profile was similar to
EN1 andMYB, although the difference from normal salivary tissues and
benign tumors was less than those in EN1 andMYB (Figure 1D).A
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Figure 1. Expression of EN1, FABP7, MYB, and VCAN distinguishes
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two-tailed Student’s t tests. P values b .05 were considered significaWe concluded that expression of EN1, FABP7, MYB, and VCAN
distinguishedACC fromnormal tissues and benign salivary gland tumors.
FABP7 Expression Is Poorly Correlated with Levels of EN1
and MYB in ACC Tumors
To distinguish one expression profile from another in our sporadic
ACCs, we determined strengths of correlation between pairs of genes
in all six combinations of all genes studied. We generated scatter plots
with trend lines to show correlations (Figure 2, A–F ). Trend line
equations and R2 values were calculated and are displayed atop each
chart. Expression levels of EN1 and VCAN (Figure 2A) and EN1 and
MYB (Figure 2B) were highly correlated. Their R2 values were
0.5646 and 0.224, respectively (R = 0.7514 and 0.4732). There was
also a moderate correlation betweenMYB and VCAN (Figure 2C; R2 =
0.1533; R = 0.3915). In contrast, FABP7 expression was poorly
correlated with EN1 or MYB expression (Figure 2, D and E ); R2
values were 0.0035 and 0.0126, respectively (R = 0.05916 and 0.1123).
FABP7 had a moderate correlation with VCAN (Figure 2F; R2 =
0.1011; R = 0.3180). Overall, FABP7 expression appeared to be
regulated differently from EN1 and MYB in ACCs.
FABP7 May Predict Poor Prognosis in Salivary ACC Patients
To determine the biologic and prognostic significance of elevated
expression of EN1, FABP7, MYB, and VCAN in ACC, we performed
overall survival analysis by generating Kaplan-Meier plots with log
rank testing (Figure 3, A–H ). Log rank testing is a hypothesisACC Normal BCA PA
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Figure 2. FABP7 expression is poorly correlated with levels of EN1 andMYB in ACC tumors. (A–F) Scatter plot analysis for the strength of a
correlation in relative gene expression between two molecules from EN1, MYB, FABP7, and VCAN. Trend lines are included. Trend line
equations and R2 values were calculated separately.
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divided our ACC cohort into two groups according to gene expression
scores. One group had expression values above the median, and the
other half’s values were below it (Figure 3, A–D). We also created
groups whose expression values were in the highest or lowest quartiles
(Figure 3, E–H ). We observed a correlation between FABP7
expression and survival (Figure 3, B and F ). Specifically, the subset
with the highest FABP7 gene expression (top quartile) had the
poorest survival (P = .006). In contrast, we found no apparent
correlation between survival and expression of the other genes
(Figure 3, A, C–E, G, and H ). These observations may explain why
FABP7 expression was not strongly correlated with EN1 and MYB
expression in ACC tumors (Figure 2). We concluded that FABP7 was
the sole predictor of poor prognosis among the genes examined here.
FABP7 Protein Expression in ACC Tumor Specimens
We performed immunohistochemistry with an FABP7 antibody on
normal salivary tissues and ACCs. Figure 4A shows that normal salivary
glands expressed FABP7 consistently in the cytoplasm of serous acinar
cells and occasionally in the nuclei of myoepithelial cells of theintercalated ducts. Moderate cytoplasmic expression was detected in
epithelial cells of the intercalated and striated ducts. Figure 4B shows a
cribriform subtype ACC from the patient shown in Figure 4A. FABP7
protein was predominantly found in the nucleus of myoepithelial cells
and, to a lesser extent, in the cytoplasm of duct-type epithelial cells.
Similar observations were made in other cribriform (Figures 4C and
S1A) and tubular pattern ACC tumors (Figures 4D and S1B).
These findings agree with previous reports that ACC is biphasic,
composed of duct-type epithelial and myoepithelial cells, and shows cell
type–specific gene expression. For example, c-Kit and EN1 expression
have been limited to duct-type epithelial cells, whereas epidermal
growth factor receptor (EGFR), p63, VCAN, and MYB have been
found exclusively in more differentiated myoepithelial cells
[14,16,17,20–22]. Nonetheless, one cribriform case with the highest
level of FABP7 mRNA (47 times normal) showed strong positive
immunoreactivity in both duct-type epithelial and myoepithelial cells
(Figure 4E ). This observation suggests that diffuse expression of FABP7
among the two cell populations might be a factor in ACC cases with
poor prognosis. Consistent with this idea, ACC cases of the solid
subtype had uniform and strong positive immunoreactivity with the
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Figure 3. FABP7may predict poor prognosis in salivary ACC patients. (A–H) Kaplan-Meier curves showing overall survival rate of patients
with sporadic ACC tumors with a higher or lower mRNA expression of EN1 (A and E), FABP7 (B and F), MYB (C and G), or VCAN gene
(D and H). The ACC cohort was divided into two groups according to relative gene expression. Panels A to D compare patients with
expression in the top half overall (red line) and the lower half (black line). Panels E to H compare expression in the higher quartile (red line)
and lower three quartile (green line) subsets. Circles identify censored data. Statistical comparisons between data sets were made with
log rank tests, and each P value is displayed. P b .05 is considered significant.
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devoid of myoepithelial cells and often associated with aggressive
behavior and poor prognosis. We concluded that increased FABP7
mRNA was linked to increased protein expression and was clinically
significant in ACC.
Discussion
Obtaining an accurate diagnosis is a major challenge for an individual
who has a rare cancer [23]. It is inevitable that most physicians will
only encounter individual rare diseases a few times during theircareers. Unfortunately, as a result, many patients are not diagnosed
until the disease has become advanced. ACC of the salivary glands is
such a rare disease [1–5]. The differential diagnosis of ACC is
difficult in the clinic because of the absence of unique clinical
symptoms, diagnostic imaging, or microscopic features. Nonethe-
less, therapies and long-term outcomes are very different for ACC
and other salivary neoplasms. The accurate diagnosis of ACC is
essential for improving patient outcomes.
We believe that gene expression analysis can complement
traditional methods of ACC diagnosis. We found that mRNA
AC
B
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D
Figure 4. FABP7 protein expression in ACC tumor specimens. (A–F) Immunohistochemistry using an antibody to FABP7. (A) Normal
salivary gland tissue. (B–F) ACC tumor specimens: cribriform (B, C, and E), tubular (D), and solid (F) patterns. (B) ACC tumor specimen
from the patient in A. (E) The cribriform case with the highest level of FABP7mRNA. (B–D) FABP7 protein was predominantly expressed in
the nucleus of myoepithelial cells and, to a lesser extent, in the cytoplasm of duct-type epithelial cells (E and F). Diffuse expression of
FABP7 protein was associated with aggressive tumor behavior and poor prognosis.
Translational Oncology Vol. 7, No. 6, 2014 FABP7 is a biomarker in adenoid cystic carcinoma Phuchareon et al. 785expression of EN1, FABP7, MYB, and VCAN distinguished ACC
from normal tissues and benign salivary gland tumors (Figure 1).
Additionally, we propose that FABP7 may be a multipurpose
molecular biomarker, because its expression was correlated with poor
prognosis (Figure 3). Expression of FABP7 may be useful for
diagnosing ACC, predicting prognosis, and searching for more
effective therapeutic options. These options may include targeting
FABP7 protein itself or upstream molecules that regulate it.
FABP7 is a member of a large family of hydrophobic proteins and
is expressed in the brain, heart, testis, and adipose tissues [24–26]. It
binds to fatty acids and other lipids and functions as a cytoplasmic
chaperone for lipid metabolism. Recent studies have found that high
levels of FABP7 were also in the nucleus of glioblastoma and
melanoma cells, and its expression was associated with reduced
survival [27–30]. We have discovered that FABP7 protein was
predominantly expressed in the nuclei of myoepithelial cells and, to a
lesser extent, in the cytoplasm of duct-type epithelial cells in both
tubular and cribriform subtypes of ACC (Figures 4, B–D, and S1, Aand B). These findings suggest a potential role of FABP7 in the
nucleus of myoepithelial cells for genesis, development, proliferation,
and maintenance of ACC tumors. In contrast, the solid subtype of
ACC, which is often correlated with a lower survival rate, had
uniform FABP7 protein expression over the malignant cells
(Figures 4F and S1C ). A similar staining pattern was seen in one
cribriform tumor harboring the highest levels of FABP7 mRNA and
was in the lowest quartile for survival. This result suggested that
diffuse expression of FABP7 protein was likely to be associated with
aggressive tumor behavior and poor prognosis (Figure 4E ).
FABP7 binds to docosahexaenoic acid (DHA), an omega-3 fatty
acid, with the highest affinity of all FABPs [31]. In a study of U87
malignant glioma cells, DHA inhibited FABP7-mediated tumor
progression by blocking the binding of arachidonic acid to FABP7
[32]. Arachidonic acid is an omega-6 fatty acid. As a result, FABP7
translocated DHA to the nucleus, where it was transferred to the
peroxisome proliferator-activated receptor gamma (PPARγ) nuclear
receptor and transactivated its downstream target genes, causing
786 FABP7 is a biomarker in adenoid cystic carcinoma Phuchareon et al. Translational Oncology Vol. 7, No. 6, 2014attenuations of proliferation and promigratory genes. Humans
naturally make small amounts of DHA but must get more from
food or supplements [33].
We do not know if DHA supplementation increases risk or benefit in
patients with ACC. If it inhibits FABP7-mediated tumor progression or
increases health benefits inACC similarly to the case inmalignant glioma
cells, DHA-rich foods such as cold water fish (e.g., salmon) or DHA
supplements may benefit patients. Of course, a randomized double blind
trial is necessary before such a recommendation can be made [34].
FABP7 is a Notch target gene [35,36]. Notch signaling is activated in
ACC [37,38]. Recent genome-wide sequencing of ACC revealed
activating mutations in genes within the Notch signaling pathway. One
study performed whole exome sequencing in a series of 24 ACC tumors
[37] and found two cases of missense and frameshift mutations in the
NOTCH1 gene and a single case of two truncating mutations in
NOTCH2. Furthermore, it identified that SPEN, a negative Notch
signaling regulator, had six truncating mutations in six ACC cases.
Another report described the exome or whole-genome sequences of 60
ACC tumor-normal pairs [38]. That report demonstrated that
components of the Notch signaling pathway including CNT2,
NOTCH1, FOXP2, DTX4, FBXW7, MAML3, and MYCN were
mutated in 13%of their cohort. That report also analyzedACC samples
with altered NOTCH1 genes using a gene set enrichment analysis and
showed a tendency toward enrichment of Notch signaling.
Given these findings, it is possible that FABP7 expression is
regulated by the Notch signaling pathway in ACC. These results are
intriguing in light of another study showing that NOTCH1
immunostaining was similar to what we observed here for FABP7
[39]. If this is the case, FABP7 may be a useful biomarker to measure
response to Notch inhibitors in salivary tumors. This approach is
both plausible biologically and attractive, in that Notch-targeted
therapeutic antibodies are currently under clinical evaluation for other
diseases [40]. This idea warrants studies addressing the links between
Notch signaling and FABP7 expression in ACC.
This report proposes FABP7 as a biomarker that can help diagnose
ACC, predict prognosis, and form a basis for more effective
therapeutic options. Establishment of FABP7 as an ACC biomarker
may aid the study of ACC in its earliest stages and will provide an
opportunity to determine the contribution of normal salivary gland
stem cells to the development of ACC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.10.003.
Acknowledgments
The authors gratefully acknowledge Kathryn Thompson, Jennifer
Dang, Kirsten Copren, Nancy Jiang, Rick Baehner, and the UCSF
Comprehensive Cancer Center Genome Analysis and Immunohis-
tochemistry and Molecular Pathology Core Facilities for their
support in TaqMan qPCR assay and immunohistochemistry.
References
[1] Spiro RH, Huvos AG, and Strong EW (1974). Adenoid cystic carcinoma of
salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128, 512–520.
[2] Phuchareon J, Ohta Y, Woo JM, Eisele DW, and Tetsu O (2009). Genetic
profiling reveals cross-contamination and misidentification of 6 adenoid cystic
carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS
One 4, e6040.
[3] Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, and Jordan RC (2010).
Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signalingduring tumor development in adenoid cystic carcinoma of the salivary glands.
Neoplasia 12, 708–717.
[4] Laurie SA and Licitra L (2006). Systemic therapy in the palliative management of
advanced salivary gland cancers. J Clin Oncol 24, 2673–2678.
[5] Liu J, Shao C, Tan ML, Mu D, Ferris RL, and Ha PK (2012). Molecular biology
of adenoid cystic carcinoma. Head Neck 34, 1665–1677.
[6] Alberico RA, Husain SH, and Sirotkin I (2004). Imaging in head and neck
oncology. Surg Oncol Clin N Am 13, 13–35.
[7] Adelstein DJ, Koyfman SA, El-Naggar AK, and Hanna EY (2012). Biology and
management of salivary gland cancers. Semin Radiat Oncol 22, 245–253.
[8] Schindler S, Nayar R, Dutra J, and Bedrossian CW (2001). Diagnostic challenges
in aspiration cytology of the salivary glands. Semin Diagn Pathol 18, 124–146.
[9] Mukunyadzi P (2002). Review of fine-needle aspiration cytology of salivary gland
neoplasms, with emphasis on differential diagnosis. Am J Clin Pathol 118,
S100–S115 [Suppl.].
[10] Mino M, Pilch BZ, and Faquin WC (2003). Expression of KIT (CD117) in
neoplasms of the head and neck: an ancillary marker for adenoid cystic
carcinoma. Mod Pathol 16, 1224–1231.
[11] Sandvik AK, Alsberg BK, Norsett KG, Yadetie F, Waldum HL, and Laegreid A
(2006). Gene expression analysis and clinical diagnosis.Clin ChimActa 363, 157–164.
[12] Finn WG (2007). Diagnostic pathology and laboratory medicine in the age of
“omics”: a paper from the 2006 William Beaumont Hospital Symposium on
Molecular Pathology. J Mol Diagn 9, 431–436.
[13] Persson M, Andren Y, Mark J, Horlings HM, Persson F, and Stenman G (2009).
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of
the breast and head and neck. Proc Natl Acad Sci U S A 106, 18740–18744.
[14] West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, Kwok S, Montgomery
KD, Varma S, and Le QT (2011). MYB expression and translocation in adenoid
cystic carcinomas and other salivary gland tumors with clinicopathologic
correlation. Am J Surg Pathol 35, 92–99.
[15] Frierson Jr HF, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T,
Moskaluk CA, and Hampton GM (2002). Large scale molecular analysis
identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J
Pathol 161, 1315–1323.
[16] Bell D, Bell A, Roberts D, Weber RS, and El-Naggar AK (2012). Developmental
transcription factor EN1—a novel biomarker in human salivary gland adenoid
cystic carcinoma. Cancer 118, 1288–1292.
[17] Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC,
Golden WL, and Frierson Jr HF (2011). Development and characterization of
xenograft model systems for adenoid cystic carcinoma. Lab Invest 91, 1480–1490.
[18] Shi X, Shen S, Liu J, Huang J, Zhou Y, and Ma S (2013). Similarity of markers
identified from cancer gene expression studies: observations from GEO. Brief
Bioinform 15, 671–684.
[19] Jeffery IB, Higgins DG, and Culhane AC (2006). Comparison and evaluation of
methods for generating differentially expressed gene lists from microarray data.
BMC Bioinformatics 7, 359.
[20] Bell D, Roberts D, Kies M, Rao P, Weber RS, and El-Naggar AK (2010). Cell
type-dependent biomarker expression in adenoid cystic carcinoma: biologic and
therapeutic implications. Cancer 116, 5749–5756.
[21] Edwards PC, Bhuiya T, and Kelsch RD (2004). Assessment of p63 expression in
the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade
adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod 97, 613–619.
[22] Cheuk W and Chan JK (2007). Advances in salivary gland pathology.
Histopathology 51, 1–20.
[23] Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L, and
RARECARE Working Group (2012). Rare cancers of the head and neck area in
Europe. Eur J Cancer 48, 783–796.
[24] Feng L and Heintz N (1995). Differentiating neurons activate transcription of
the brain lipid-binding protein gene in radial glia through a novel regulatory
element. Development 121, 1719–1730.
[25] Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, and Fujiwara T (1997).
Isolation and expression of a cDNA for human brain fatty acid-binding protein
(B-FABP). Biochim Biophys Acta 1354, 24–28.
[26] Storch J and Thumser AE (2010). Tissue-specific functions in the fatty
acid-binding protein family. J Biol Chem 285, 32679–32683.
[27] Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK,
Lamborn KR, Berger MS, Botstein D, and Brown PO, et al (2005). Gene
expression profiling reveals molecularly and clinically distinct subtypes of
glioblastoma multiforme. Proc Natl Acad Sci USA 102, 5814–5819.
Translational Oncology Vol. 7, No. 6, 2014 FABP7 is a biomarker in adenoid cystic carcinoma Phuchareon et al. 787[28] Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H,
TakataM, Aburatani H, andHoonDS, et al (2006). A newmelanoma antigen fatty
acid-binding protein 7, involved in proliferation and invasion, is a potential target
for immunotherapy and molecular target therapy. Cancer Res 66, 4443–4449.
[29] Slipicevic A, Jorgensen K, Skrede M, Rosnes AK, Troen G, Davidson B, and
Florenes VA (2008). The fatty acid binding protein 7 (FABP7) is involved in
proliferation and invasion of melanoma cells. BMC Cancer 8, 276.
[30] Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, Nguyen L,
Nguyen T, Ye X, andMortonDL, et al (2010). Aberrant fatty acid-binding protein-7
gene expression in cutaneous malignant melanoma. J Invest Dermatol 130, 221–229.
[31] Xu LZ, Sánchez R, Sali A, and Heintz N (1996). Ligand specificity of brain
lipid-binding protein. J Biol Chem 271, 24711–24719.
[32] Mita R, Beaulieu MJ, Field C, and Godbout R (2010). Brain fatty acid-binding
protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant
glioma cell migration. J Biol Chem 285, 37005–37015.
[33] Horrocks LA and Yeo YK (1999). Health benefits of docosahexaenoic acid
(DHA). Pharmacol Res 40, 211–225.
[34] Merendino N, Costantini L, Manzi L, Molinari R, D'Eliseo D, and Velotti F
(2013). Dietary ω-3 polyunsaturated fatty acid DHA: a potentialadjuvant in the treatment of cancer. Biomed Res Int 2013, 310186. doi:
10.1155/2013/310186.
[35] Anthony TE, Mason HA, Gridley T, Fishell G, and Heintz N (2005). Brain
lipid-binding protein is a direct target of Notch signaling in radial glial cells.
Genes Dev 19, 1028–1033.
[36] Bray SJ (2006). Notch signalling: a simple pathway becomes complex. Nat Rev
Mol Cell Biol 7, 678–689.
[37] Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS,
Papaemmanuil E, Cheverton A, Bignell GR, and Butler AP, et al (2013). Whole
exome sequencing of adenoid cystic carcinoma. J Clin Invest 123, 2965–2968.
[38] Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D,
Walsh LA, Eng S, and Huse JT, et al (2013). The mutational landscape of
adenoid cystic carcinoma. Nat Genet 45, 791–798.
[39] Bell D, Hanna EY, Miele L, Roberts D, Weber RS, and El-Naggar AK (2014).
Expression and significance of notch signaling pathway in salivary adenoid cystic
carcinoma. Ann Diagn Pathol 18, 10–13.
[40] Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D,
Venook R, Wu X, and Ridgway J, et al (2010). Therapeutic antibody targeting of
individual Notch receptors. Nature 464, 1052–1057.
